For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
SPORE in Prostate Cancer

You are here

Dr. Brian Robinson

Biospecimen and Pathology Core Co-Leader

Dr. Robinson is a board-certified anatomic pathologist with subspecialty interest in genitourinary (GU) pathology. After finishing residency at NY-Presbyterian Hospital/Weill Cornell, he completed a GU pathology fellowship with Dr. Jonathan Epstein at The Johns Hopkins Hospital. He serves as Chief of Surgical Pathology at Weill Cornell as well as Co-Chief of Urologic Pathology.  In addition to his clinical work within the Department of Pathology & Laboratory Medicine at Weill Cornell, he is a member of the Institute for Precision Medicine, serving as part of the pathology team.

He is also actively involved in The Cancer Genome Atlas (TCGA) project, serving as an expert pathologist and analysis working group member for both prostate cancer and bladder cancer. Dr. Robinson is Co-Director of the Biospecimen/Pathology Core Facility at Weill Cornell, working closely with his colleagues to ensure collection and annotation of the highest quality specimens as well as provision of core pathology services.

As a dedicated, fellowship-trained urologic pathologist and co-director of the Biospecimen/Pathology Core Facility at Well Cornell Medical Center, his expertise is in the examination, processing, and analysis of genitourinary cancers, including kidney, bladder, and prostate. His most recent work has focused on the molecular pathology of prostate cancer, particularly the genetics of advanced prostate cancer and neuroendocrine prostate cancer. In addition to the study of lethal prostate cancers, his group also focuses on identifying racial differences in prostate cancer with the hope of better understanding the drivers of prostate cancer in African-American men and why they have a more aggressive disease with worse outcomes compared to Caucasian men. Through all of this research, his team aims to identify biomarkers of aggressive disease in order to allow earlier diagnosis and prevent cancer-related deaths.

Weill Cornell Medicine SPORE in Prostate Cancer Belfer Research Building
413 E. 69th St.
New York, NY 10021 Phone: (646) 962-6184